These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 8831812

  • 1. Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
    Spracklin DK, Kharasch ED.
    Chem Res Toxicol; 1996 Jun; 9(4):696-702. PubMed ID: 8831812
    [Abstract] [Full Text] [Related]

  • 2. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats.
    Kharasch ED, Jubert C, Spracklin DK, Hoffman GM.
    Toxicol Appl Pharmacol; 1999 Oct 01; 160(1):49-59. PubMed ID: 10502502
    [Abstract] [Full Text] [Related]

  • 3. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
    Sheffels P, Schroeder JL, Altuntas TG, Liggitt HD, Kharasch ED.
    Chem Res Toxicol; 2004 Sep 01; 17(9):1177-89. PubMed ID: 15377151
    [Abstract] [Full Text] [Related]

  • 4. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A).
    Iyer RA, Anders MW.
    Chem Res Toxicol; 1997 Jul 01; 10(7):811-9. PubMed ID: 9250416
    [Abstract] [Full Text] [Related]

  • 5. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
    Gul Altuntas T, Kharasch ED.
    Drug Metab Dispos; 2002 Feb 01; 30(2):148-54. PubMed ID: 11792683
    [Abstract] [Full Text] [Related]

  • 6. Sulfoxidation of cysteine and mercapturic acid conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A).
    Altuntas TG, Park SB, Kharasch ED.
    Chem Res Toxicol; 2004 Mar 01; 17(3):435-45. PubMed ID: 15025515
    [Abstract] [Full Text] [Related]

  • 7. Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
    Altuntas TG, Kharasch ED.
    Toxicol Appl Pharmacol; 2001 Dec 01; 177(2):85-93. PubMed ID: 11740907
    [Abstract] [Full Text] [Related]

  • 8. Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane.
    Jin L, Davis MR, Kharasch ED, Doss GA, Baillie TA.
    Chem Res Toxicol; 1996 Mar 01; 9(2):555-61. PubMed ID: 8839062
    [Abstract] [Full Text] [Related]

  • 9. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
    Altuntas TG, Zager RA, Kharasch ED.
    Toxicol Appl Pharmacol; 2003 Nov 15; 193(1):55-65. PubMed ID: 14613716
    [Abstract] [Full Text] [Related]

  • 10. P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product.
    Kharasch ED, Hankins DC.
    Drug Metab Dispos; 1996 Jun 15; 24(6):649-54. PubMed ID: 8781780
    [Abstract] [Full Text] [Related]

  • 11. Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("compound A") in rats.
    Kharasch ED, Schroeder JL, Bammler T, Beyer R, Srinouanprachanh S.
    Toxicol Sci; 2006 Apr 15; 90(2):419-31. PubMed ID: 16384817
    [Abstract] [Full Text] [Related]

  • 12. Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
    Kharasch ED, Thorning D, Garton K, Hankins DC, Kilty CG.
    Anesthesiology; 1997 Jan 15; 86(1):160-71. PubMed ID: 9009951
    [Abstract] [Full Text] [Related]

  • 13. Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in male Fischer 344 rats.
    Iyer RA, Baggs RB, Anders MW.
    J Pharmacol Exp Ther; 1997 Dec 15; 283(3):1544-51. PubMed ID: 9400032
    [Abstract] [Full Text] [Related]

  • 14. Cysteine conjugate beta-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A.
    Iyer RA, Frink EJ, Ebert TJ, Anders MW.
    Anesthesiology; 1998 Mar 15; 88(3):611-8. PubMed ID: 9523802
    [Abstract] [Full Text] [Related]

  • 15. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
    Jin L, Baillie TA, Davis MR, Kharasch ED.
    Biochem Biophys Res Commun; 1995 May 16; 210(2):498-506. PubMed ID: 7755627
    [Abstract] [Full Text] [Related]

  • 16. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison.
    Kharasch ED, Jubert C.
    Anesthesiology; 1999 Nov 16; 91(5):1267-78. PubMed ID: 10551576
    [Abstract] [Full Text] [Related]

  • 17. Cysteine conjugate beta-lyase-catalyzed bioactivation of bromine-containing cysteine S-conjugates: stoichiometry and formation of 2,2-difluoro-3-halothiiranes.
    Finkelstein MB, Dekant W, Anders MW.
    Chem Res Toxicol; 1996 Nov 16; 9(1):227-31. PubMed ID: 8924595
    [Abstract] [Full Text] [Related]

  • 18. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria.
    Iyer RA, Anders MW.
    Anesthesiology; 1996 Dec 16; 85(6):1454-61. PubMed ID: 8968194
    [Abstract] [Full Text] [Related]

  • 19. Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
    Kharasch ED, Hoffman GM, Thorning D, Hankins DC, Kilty CG.
    Anesthesiology; 1998 Jun 16; 88(6):1624-33. PubMed ID: 9637657
    [Abstract] [Full Text] [Related]

  • 20. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
    Njoku DB, Pohl LR, Sokoloski EA, Marchick MR, Borkowf CB, Martin JL.
    Anesthesiology; 1999 Feb 16; 90(2):458-69. PubMed ID: 9952153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.